The Lobb Law Firm Company Overview, Contact Details & Competitors

Q: What is The Lobb Law Firm's official website and social media links?

The Lobb Law Firm's official website is thelobblawfirm.com. The Lobb Law Firm has social profiles on LinkedIn.

Q: How many employees does The Lobb Law Firm have currently?

The Lobb Law Firm has approximately 10 employees.

Q: What technology does The Lobb Law Firm use?

The Lobb Law Firm's tech stack includes Swiper, Google Analytics, Microsoft 365, MailChimp for WordPress, Facebook.

Insights

Gathering insights about The Lobb Law Firm…

Similar companies to The Lobb Law Firm

The Lobb Law Firm Tech Stack

The Lobb Law Firm uses 8 technology products and services including LiteSpeed Cache, Slick, jQuery, and more. Explore The Lobb Law Firm's tech stack below.

LiteSpeed Cache
Caching
Slick
Javascript Libraries
jQuery
Javascript Libraries
Lodash
Javascript Libraries
Google Maps
Maps
Alli
Search Engines
Google Analytics
Web Analytics
Contact Form 7
Web Platform Extensions

Media & News

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
– Company on track to begin ELEVATE-45-201 in Q3 2025 – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-45-201 – BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it has received authorization from the Health Authorities and Ethics Committees of multiple countries under the European Union Clinical Trial Regulation (EU-CTR) to initiate ELEVATE-45-201, a Phase 1/2 multiple ascending dose (MAD) clinical study of ENTR-601-45 in patients living with Duchenne muscular dystrophy (DMD) who are amenable to exon 45 skipping. “ELEVATE-45-201 is the most advanced clinical study of a conjugated exon skipping therapy for individuals amenable to exon 45 skipping and offers the potential to address a large Duchenne subpopulation with significant unmet medical needs,” said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics.
May 28, 2025 | www.globenewswire.com
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
– Company on track to initiate ELEVATE-45-201 study in Q3 2025 – – ELEVATE-45 regulatory filings submitted in the EU, with regulatory review ongoing – – ELEVATE-45 is the second of three novel exon skipping Duchenne programs the Company expects to progress into global clinical development in 2025 – BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it has received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee to initiate ELEVATE-45-201. ELEVATE-45-201 is a Phase 1/2 multiple ascending dose (MAD) clinical study to evaluate Entrada's investigational medicinal product ENTR-601-45 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation in the DMD gene amenable to exon 45 skipping.
Mar 24, 2025 | www.globenewswire.com
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44
– Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – – Follows recently received Medicines and Healthcare Products Regulatory Agency authorization in the United Kingdom for ELEVATE-44-201 – – Expands global ELEVATE-44 clinical program to include pediatric, adult, ambulatory and non-ambulatory patients with Duchenne muscular dystrophy – BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the United States Food and Drug Administration (FDA) has lifted the clinical hold on ENTR-601-44 and provided authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose (MAD) clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (DMD) in adult patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping. The global ELEVATE-44 program, which includes the ELEVATE-44-102 study in the U.S. and ELEVATE-44-201 outside of the U.S., will cover a broad population of patients with DMD and support evaluation of ENTR-601-44 in patients with both early and advanced disease.
Feb 24, 2025 | www.globenewswire.com
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy
– Company on track to initiate ELEVATE-44-201 in Q2 2025 – – ENTR-601-44 regulatory filings submitted in additional geographies including the U.S. and EU, with regulatory discussions ongoing – BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced it had received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee for its Clinical Trial of an Investigational Medicinal Product to initiate ELEVATE-44-201, a Phase 1/2 multiple ascending dose (MAD) clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping. “The clearance by the MHRA marks a new phase in Entrada's growth and, most importantly, moves us closer to realizing our commitment to families living with Duchenne muscular dystrophy,” said Dipal Doshi, Chief Executive Officer of Entrada Therapeutics.
Feb 03, 2025 | www.globenewswire.com
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
– ENTR-601-44 was well-tolerated in healthy volunteers with no serious adverse events, no drug-related adverse events and no clinically significant changes or trends noted in vital signs, ECGs, physical exams or laboratory assessments –
Jun 24, 2024 | www.globenewswire.com
This Week in ETFs: 7 New ETFs Dwarfed by 11 Closures
During the past week, in the wake of the Exchange conference, launches of new ETFs started to pick up again from their recent lull. A total of seven funds rolled out during the week, while several issuers announced or completed ETF closures.
Feb 23, 2024 | www.etftrends.com
ETF of the Week: ERShares Entrepreneurs ETF (ENTR)
VettaFi's vice chairman Tom Lydon discussed the ERShares Entrepreneurs ETF (ENTR) on this week's “ETF of the Week” podcast with Chuck Jaffe of “Money Life.” Entrepreneurial companies are on fire, positioning the ERShares Entrepreneurs ETF (ENTR) among the rising ETFs.
Apr 06, 2023 | www.etftrends.com

The Lobb Law Firm's Email Address Formats

The Lobb Law Firm uses at least 1 format(s):

The Lobb Law Firm Email Formats	Example	Percentage
First@thelobblawfirm.com	John@thelobblawfirm.com	35%
FirstLast@thelobblawfirm.com	JohnDoe@thelobblawfirm.com	15%
First@thelobblawfirm.com	John@thelobblawfirm.com	35%
FirstLast@thelobblawfirm.com	JohnDoe@thelobblawfirm.com	15%

Frequently Asked Questions

Where is The Lobb Law Firm's headquarters located?

The Lobb Law Firm's main headquarters is located at 24681 Northwestern Highway 4100 Southfield, Michigan 48075 United States. The company has employees across 3 continents, including North AmericaAfricaAsia.

What is The Lobb Law Firm's stock symbol?

The Lobb Law Firm is a publicly traded company; the company's stock symbol is ENTR.

What is The Lobb Law Firm's official website and social media links?

The Lobb Law Firm's official website is thelobblawfirm.com and has social profiles on LinkedIn.

What is The Lobb Law Firm's NAICS code?

The Lobb Law Firm's NAICS code is 5411 - Legal Services.

How many employees does The Lobb Law Firm have currently?

As of February 2026, The Lobb Law Firm has approximately 10 employees across 3 continents, including North AmericaAfricaAsia. Key team members include Chief Operating Officer: B. J.President: J. L.Finance Manager: K. B.. Explore The Lobb Law Firm's employee directory with LeadIQ.

What industry does The Lobb Law Firm belong to?

The Lobb Law Firm operates in the Legal Services industry.

What technology does The Lobb Law Firm use?

The Lobb Law Firm's tech stack includes LiteSpeed CacheSlickjQueryLodashGoogle MapsAlliGoogle AnalyticsContact Form 7.

What is The Lobb Law Firm's email format?

The Lobb Law Firm's email format typically follows the pattern of First@thelobblawfirm.com. Find more The Lobb Law Firm email formats with LeadIQ.

When was The Lobb Law Firm founded?

The Lobb Law Firm was founded in 1976.

Insights

Similar companies to The Lobb Law Firm

Motley Rice LLC

Cellino & Barnes

Morgan & Morgan

The Lobb Law Firm Tech Stack

Media & News

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

This Week in ETFs: 7 New ETFs Dwarfed by 11 Closures

ETF of the Week: ERShares Entrepreneurs ETF (ENTR)

The Lobb Law Firm's Email Address Formats

Frequently Asked Questions

Where is The Lobb Law Firm's headquarters located?

What is The Lobb Law Firm's stock symbol?

What is The Lobb Law Firm's official website and social media links?

What is The Lobb Law Firm's NAICS code?

How many employees does The Lobb Law Firm have currently?

What industry does The Lobb Law Firm belong to?

What technology does The Lobb Law Firm use?

What is The Lobb Law Firm's email format?

When was The Lobb Law Firm founded?

The Lobb Law Firm

Company Overview

Media & News

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?